☰

Bob Carter, MD - Publications

Affiliations: 
2010-2017 University of California, San Diego, La Jolla, CA 
 2017- Neurosurgery Massachusetts General Hospital, Boston, MA 
Tree Info Similar researchers PubMed Report error

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Ricklefs FL, Maire CL, Matschke J, Dührsen L, Sauvigny T, Holz M, Kolbe K, Peine S, Herold-Mende C, Carter B, Chiocca EA, Lawler SE, Westphal M, Lamszus K. FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles. International Journal of Molecular Sciences. 21. PMID 32178271 DOI: 10.3390/Ijms21061931  0.312
2018 Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu P, et al. Durable Complete Responses in Some Recurrent High Grade Glioma Patients Treated with Toca 511 & Toca FC. Neuro-Oncology. PMID 29762717 DOI: 10.1093/Neuonc/Noy075  0.323
2018 Cloughesy TF, Landolfi J, Vogelbaum M, Ostertag D, Elder B, Carter B, Chen CC, Kalkanis S, Kesari S, Lai A, Lee I, Liau L, Mikkelsen T, Nghiemphu L, Piccioni D, et al. Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A085  0.35
2018 Accomando W, Cloughesy T, Kalkanis S, Mikkelsen T, Landolfi J, Carter B, Chen C, Vogelbaum M, Elder J, Piccioni D, Walbert T, Hogan D, Diago O, Gammon D, Haghighi A, et al. ATIM-26. IMMUNOLOGIC TRENDS ASSOCIATED WITH PATIENT OUTCOMES IN A PHASE 1 CLINICAL TRIAL OF TOCA 511 AND TOCA FC IN RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 20: vi6-vi7. DOI: 10.1093/Neuonc/Noy148.021  0.303
2018 Lanman TA, Compton JN, Carroll KT, Hirshman BR, Ali MA, Lochte B, Carter B, Chen CC. Survival patterns of oligoastrocytoma patients: A surveillance, epidemiology and end results (SEER) based analysis Interdisciplinary Neurosurgery. 11: 70-75. DOI: 10.1016/J.Inat.2017.07.017  0.341
2017 Carroll KT, Hirshman B, Ali MA, Alattar AA, Brandel MG, Lochte B, Lanman T, Carter B, Chen CC. Management and Survival Patterns of Patients with Gliomatosis Cerebri: a SEER-based Analysis. World Neurosurgery. PMID 28366748 DOI: 10.1016/J.Wneu.2017.03.103  0.334
2017 Cloughesy TF, Ostertag D, Landolfi JC, Walbert T, Vogelbaum MA, Elder JB, Bloomfield S, Carter B, Chen C, Kalkanis SN, Kesari S, Lai A, Lee I, Liau LM, Mikkelsen T, et al. Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC. Journal of Clinical Oncology. 35: e13504-e13504. DOI: 10.1200/Jco.2017.35.15_Suppl.E13504  0.351
2017 Cloughesy T, Landolfi J, Vogelbaum M, Ostertag D, Elder B, Carter B, Chen C, Kalkanis S, Lai A, Mikkelsen T, Nghiemphu P, Piccioni D, Accomando W, Diago O, Hogan D, et al. ATIM-02. DURABLE RESPONSES OBSERVED IN IDH1 WILDTYPE AND MUTANT RECURRENT HIGH GRADE GLIOMA (rHGG) WITH TOCA 511 & TOCA FC TREATMENT Neuro-Oncology. 19: vi26-vi26. DOI: 10.1093/Neuonc/Nox168.099  0.352
2017 Li J, Kaneda M, Patel K, Wang J, Akers J, Ramakrishnan V, Jiang T, Carter B, Varner J, Chen C. OS06.7 PI-3Kγ inhibition suppresses glioblastoma tumorigenicity through disruption of an IL11-STAT3-MYC signaling axis between microglia and glioblastoma Neuro-Oncology. 19: iii12-iii12. DOI: 10.1093/Neuonc/Nox036.041  0.301
2016 Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu PL, Piccioni D, et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine. 8: 341ra75. PMID 27252174 DOI: 10.1126/Scitranslmed.Aad9784  0.331
2015 Steed T, Treiber J, Patel K, Carter B, Dale A, Chow L, Chen C. Nimg-09Quantification Of Glioblastoma Localization Reveals Associations With Genomic Subtypes And Subventricular Zone Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov225.09  0.315
2015 Dong X, Alattar A, Padwal J, Brandel M, Carter B, Chen C. EPID-10GROSS TOTAL RESECTION IS NOT ASSOCIATED WITH IMPROVED OVERALL SURVIVAL RELATIVE TO SUBTOTAL RESECTION IN PATIENTS WITH OLIGODENDROGLIOMAS, ANAPLASTIC OLIGODENDROGLIOMAS, AND OLIGOASTROCYTOMAS Neuro-Oncology. 17: v80.2-v80. DOI: 10.1093/Neuonc/Nov213.10  0.353
2015 Dong X, Noorbakhsh A, Hirshman B, Zhou T, Tang J, Chang D, Carter B, Chen C. EPID-09IMPROVED SURVIVAL OF LOW-GRADE GLIOMA PATIENTS (1999-2010) DESPITE DECREASED UTILIZATION OF RADIATION THERAPY: A SEER-BASED ANALYSIS. Neuro-Oncology. 17: v80.1-v80. DOI: 10.1093/Neuonc/Nov213.09  0.332
2015 Marcus L, Marshall D, McCutcheon B, Gonda D, Goetsch S, Hattangadi J, Carter B, Yamamoto M, Chen C. Bmet-09Cumulative Intracranial Tumor Volume (Citv) Enhances The Prognostic Value Of The Lung-Specific-Graded Prognostic Assessment (Gpa) Model Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov208.09  0.307
2015 Lai G, Mahadevan A, Hackney D, Warnke P, Kasper E, Wong E, Carter B, Chen C. BMET-08DIAGNOSTIC ACCURACY OF PET, SPECT, AND ASL IN DIFFERENTIATING TUMOR RECURRENCE FROM NECROSIS IN CEREBRAL METASTASIS POST-STEREOTACTIC RADIOSURGERY Neuro-Oncology. 17: v46.3-v46. DOI: 10.1093/Neuonc/Nov208.08  0.316
2015 Marshall D, Marcus L, McCutcheon B, Goetsch S, Alksne J, Ott K, Carter B, Hattangadi J, Koiso T, Yamamoto M, Chen C. BMET-07SURVIVAL PATTERNS OF PATIENTS WITH CEREBRAL METASTASES WHO UNDERWENT MULTIPLE ROUNDS OF STEREOTACTIC RADIOSURGERY (SRS) Neuro-Oncology. 17: v46.2-v46. DOI: 10.1093/Neuonc/Nov208.07  0.345
2014 Chen C, Gonda D, Kim T, Goetsch S, Kawabe T, Watanabe S, Alksne J, Hattangadi J, Ott K, Hodgens D, Carter B, Yamamoto M. BM-08 * PROGNOSTIC FACTORS FOR SRS-TREATED PATIENTS WITH CEREBRAL METASTASIS: IMPLICATIONS ON RANDOMIZED CONTROL TRIAL DESIGN AND INTER-INSTITUTIONAL COLLABORATIVE EFFORTS Neuro-Oncology. 16: v33-v33. DOI: 10.1093/Neuonc/Nou240.8  0.349
2013 Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, ... ... Carter B, et al. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. Journal of Neurosurgery. 118: 1183-7. PMID 23451905 DOI: 10.3171/2013.1.Jns12397  0.31
2012 Bartek J, Ng K, Bartek J, Fischer W, Carter B, Chen CC. Key concepts in glioblastoma therapy. Journal of Neurology, Neurosurgery, and Psychiatry. 83: 753-60. PMID 22396442 DOI: 10.1136/Jnnp-2011-300709  0.304
2011 Noerholm M, Bentink S, Strand M, Ter-Ovanesyan D, Lundin E, Ohlson N, Ottander U, Balaj L, Limperg T, Salehi A, Zhu LD, Hochberg F, Breakefield X, Carter B, Skog J. Abstract C140: RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and ovarian cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C140  0.325
Show low-probability matches.